What happened, in summary

A 74-year-old man was diagnosed in September 2018 with Stage IV extensive-disease small cell lung cancer involving lymph nodes, liver, and bone. He began first-line carboplatin and etoposide and completed four cycles by January 2019, achieving a partial response.

About nine weeks later, he was readmitted with worsening shortness of breath, abdominal swelling, and rapidly progressive diffuse liver metastases. The liver involvement caused severe liver dysfunction and initially made further systemic chemotherapy unsafe. He therefore received palliative radiation to the whole liver. Within about two weeks, his abdominal symptoms and liver tests improved enough for treatment to continue.

He then received second-line amrubicin and completed three courses. The benefit was temporary: in late June 2019, imaging again showed progression of multiple liver metastases. A lower-limb fracture and worsening performance status meant additional chemotherapy was no longer pursued. Care shifted to supportive treatment, and he died in a palliative care unit on July 27, 2019. His course shows how palliative radiation briefly improved symptoms and organ function enough to allow another period of cancer treatment.